Cytokinetics, Inc. Investigated by the Portnoy Lawfirm

Core Viewpoint - Cytokinetics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the New Drug Application (NDA) for aficamten, which may have caused financial losses for investors [1][3]. Group 1: Class Action Details - The class action is on behalf of investors who purchased Cytokinetics securities between December 27, 2023, and May 6, 2025, with a deadline for filing a lead plaintiff motion set for November 17, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for legal rights discussions and case evaluations [2]. Group 2: Allegations Against Cytokinetics - The complaint alleges that during the class period, Cytokinetics made materially false and misleading statements about the NDA submission and approval timeline for aficamten, specifically expecting FDA approval in the second half of 2025 [3]. - The company failed to disclose significant risks related to the submission of a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process, leading to financial losses for shareholders when the truth was revealed [3].